US 12,410,238 B2Granted

Monoclonal antibodies against JC virus

AssigneeIcahn School of Medicine at Mount Sinai

InventorsThomas Moran, Thomas Kraus, J. Andrew Duty, Domenico Tortorella

Life of this patent

Estimating the term…

Abstract

Provided herein are monoclonal antibodies and antigen-binding fragments thereof that bind to the John Cunningham virus. Also provided are pharmaceutical compositions comprising the monoclonal antibodies and antigen-binding fragments thereof, as well as methods of using such monoclonal antibodies and antigen-binding fragments thereof, including methods for the treatment and/or prevention of JCV infections and/or progressive multifocal leukoencephalopathy.

Claims28

Dependent claims

An antibody or antigen-binding fragment thereof which binds to the John Cunningham virus (JCV), the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region;

wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3;
and wherein:
(a) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:5, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(b) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:1, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(c) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:25, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(d) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:26, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(e) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:14, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:37, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(f) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:4, CDR2H comprises SEQ ID NO:15, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(g) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:29, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO:
48;
(h) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:30, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO:
49;
(i) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:18, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AAS, and CDR3L comprises SEQ ID NO:51;
(j) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:19, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AVS, and CDR3L comprises SEQ ID NO:52;
(k) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:11, CDR2H comprises SEQ ID NO:22, CDR3H comprises SEQ ID NO:35, CDR1L comprises SEQ ID NO:44, CDR2L comprises the sequence GTS, and CDR3L comprises SEQ ID NO:55;
(l) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:9, CDR2H comprises SEQ ID NO:20, CDR3H comprises SEQ ID NO:33, CDR1L comprises SEQ ID NO:42, CDR2L comprises the sequence WAS, and CDR3L comprises SEQ ID NO:53;
or
(m) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:10, CDR2H comprises SEQ ID NO:21, CDR3H comprises SEQ ID NO:34, CDR1L comprises SEQ ID NO:43, CDR2L comprises the sequence GAS, and CDR3L comprises SEQ ID NO:54.

15 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/620,496Filed 19 Jun 2020 · us provisional application
Priority: 19 Jun 2019
Published: US 2022/0356228 A110 Nov 2022
Granted: 9 Sep 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/08
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from viruses
C12N 15/63
Recombinant DNA-technology: introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61P 31/20
Antivirals: for DNA viruses

Family

Application62/863,433Us provisional application · filed 19 Jun 2019
US 2022/0356228 A1Pre-grant publication · published 10 Nov 2022
US 12,410,238 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3;
and wherein:
(a) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:5, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(b) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:1, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:23, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(c) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:25, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(d) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:12, CDR3H comprises SEQ ID NO:26, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(e) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:3, CDR2H comprises SEQ ID NO:14, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:37, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(f) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:4, CDR2H comprises SEQ ID NO:15, CDR3H comprises SEQ ID NO:28, CDR1L comprises SEQ ID NO:36, CDR2L comprises the sequence KVS, and CDR3L comprises SEQ ID NO:45;
(g) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:29, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO:
48;
(h) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:6, CDR2H comprises SEQ ID NO:16, CDR3H comprises SEQ ID NO:30, CDR1L comprises SEQ ID NO:39, CDR2L comprises the sequence WAS, CDR3L comprises SEQ ID NO:
49;
(i) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:18, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AAS, and CDR3L comprises SEQ ID NO:51;
(j) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:8, CDR2H comprises SEQ ID NO:19, CDR3H comprises SEQ ID NO:32, CDR1L comprises SEQ ID NO:41, CDR2L comprises the sequence AVS, and CDR3L comprises SEQ ID NO:52;
(k) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:11, CDR2H comprises SEQ ID NO:22, CDR3H comprises SEQ ID NO:35, CDR1L comprises SEQ ID NO:44, CDR2L comprises the sequence GTS, and CDR3L comprises SEQ ID NO:55;
(l) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:9, CDR2H comprises SEQ ID NO:20, CDR3H comprises SEQ ID NO:33, CDR1L comprises SEQ ID NO:42, CDR2L comprises the sequence WAS, and CDR3L comprises SEQ ID NO:53;
or
(m) CDR1H of the antibody or antigen-binding fragment thereof comprises SEQ ID NO:10, CDR2H comprises SEQ ID NO:21, CDR3H comprises SEQ ID NO:34, CDR1L comprises SEQ ID NO:43, CDR2L comprises the sequence GAS, and CDR3L comprises SEQ ID NO:54.

15 more elements

Facts

Application

17/620,496Filed 19 Jun 2020 · us provisional application

Priority

19 Jun 2019

Published

US 2022/0356228 A110 Nov 2022

Granted

9 Sep 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/08
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from viruses
C12N 15/63
Recombinant DNA-technology: introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61P 31/20
Antivirals: for DNA viruses